CNBC February 16, 2024
Cheryl Winokur Munk

Key Points

– Consumers are clamoring for weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound despite a monthly cost as high as $1,000 to $1,500, and using every discount they can source to lower the price.

– While a majority of corporate health insurance plans offer GLP-1 drug coverage for diabetes, only about one-quarter extend that to weight loss, according to a recent survey.

– But employer interest is rising, and employee benefits experts say it’s a matter of when, not if, more company insurance plans will cover the in-demand obesity treatments.

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss.

Despite the hefty price...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Employer, Insurance, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Self-insured
Elevance Health sees double-digit profit growth in Q1, posting $2.2 B in earnings
Elevance Health posts $2.2B profit in Q1
Patient advocates shred Becerra's copay accumulator comments
Racial health disparities exist in every state, new report says
Elevance Health Boosts Behavioral Health Biz with $740M State Contracts

Share This Article